Compare DSP Healthcare Fund vs UTI Healthcare Fund
Risk | Very High | Very High |
Rating | 4.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.93 | 2.28 |
NAV | ₹37.70 | ₹269.31 |
Fund Started | 12 Nov 2018 | 01 Aug 2005 |
Fund Size | ₹3114.33 Cr | ₹1101.63 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
4.0
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.93
2.28
NAV
₹37.70
₹269.31
Fund Started
12 Nov 2018
01 Aug 2005
Fund Size
₹3114.33 Cr
₹1101.63 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 30 days.
1 Year | -4.95% | -3.53% |
3 Year | 20.42% | 22.40% |
5 Year | 14.48% | 13.59% |
1 Year
-4.95%
-3.53%
3 Year
20.42%
22.40%
5 Year
14.48%
13.59%
Equity | 98.20% | 99.40% |
Cash | 1.80% | 0.59% |
Equity
98.20%
99.40%
Cash
1.80%
0.59%
Top 10 Holdings |
|
|
Top 10 Holdings
Cipla Ltd. | 8.69% |
Sun Pharmaceutical Industries Ltd. | 8.48% |
Ipca Laboratories Ltd. | 7.73% |
Globus Medical Inc | 6.78% |
Laurus Labs Ltd. | 6.52% |
Illumina Inc. (USA) | 6.07% |
Sai Life Sciences Ltd. | 5.23% |
Gland Pharma Ltd. | 5.09% |
Cohance Lifesciences Ltd. | 5.04% |
Apollo Hospitals Enterprise Ltd. | 4.40% |
Sun Pharmaceutical Industries Ltd. | 9.37% |
Ajanta Pharma Ltd. | 7.16% |
Lupin Ltd. | 5.65% |
Glenmark Pharmaceuticals Ltd. | 4.06% |
Gland Pharma Ltd. | 3.60% |
Procter & Gamble Health Ltd. | 3.46% |
Dr. Reddy's Laboratories Ltd. | 3.46% |
Cipla Ltd. | 3.43% |
Alkem Laboratories Ltd. | 3.40% |
Apollo Hospitals Enterprise Ltd. | 3.39% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 12 Nov 2018 | 01 Aug 2005 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
12 Nov 2018
01 Aug 2005